Functional Dyspepsia (FD) is a common affliction in western countries effecting approximately 25% of the population. Due to its heterogeneous pathogenesis, effective therapeutics are limited. Mosapride, a serotonin receptor agonist with enterokinetic properties, has been evaluated for treating dyspeptic symptoms in a limited number of clinical trials. Most trials found mosapride to be as effective as other commonly used treatments for FD including histamine receptor blockers (H2RAs), and the results of the only randomized double-blind placebo-controlled trial to date found mosapride to be no more effective than placebo. These studies were limited by suboptimal study design and performed prior to sub-classification of FD sub-types as defined by Rome III. Therefore, there is currently inadequate data to comment on the efficacy of mosapride for treating FD. Larger placebo controlled trials differentiating dyspeptic patients by primary symptom associations are necessary.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
Publishing in Gene Regulation and Systems Biology was a very positive experience. I was impressed by the fast and uncomplicated submission process as well as the clear and professional peer review process which helped to improve the manuscript. The Libertas Academica team was very patient and helpful. I would definitely recommend the journal to other colleagues in the field!
All authors are surveyed after their articles are published. Authors are asked to rate their experience in a variety of areas, and their responses help us to monitor our performance. Presented here are their responses in some key areas. No 'poor' or 'very poor' responses were received; these are represented in the 'other' category.See Our Results
Copyright © 2013 Libertas Academica Ltd (except open access articles and accompanying metadata and supplementary files.)